We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Steris (STE) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
Wall Street analysts expect Steris (STE - Free Report) to post quarterly earnings of $2.11 per share in its upcoming report, which indicates a year-over-year increase of 3.9%. Revenues are expected to be $1.34 billion, down 0.4% from the year-ago quarter.
Over the last 30 days, there has been a downward revision of 1.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Steris metrics that Wall Street analysts commonly model and monitor.
Analysts' assessment points toward 'Revenues- Healthcare' reaching $950.73 million. The estimate indicates a year-over-year change of +9.3%.
Based on the collective assessment of analysts, 'Revenues- Healthcare Products- Service' should arrive at $342.16 million. The estimate points to a change of +10.7% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Healthcare Products- Capital equipment' of $267.10 million. The estimate indicates a year-over-year change of +4.8%.
The average prediction of analysts places 'Revenues- Healthcare Products- Consumables' at $338.19 million. The estimate suggests a change of +10.5% year over year.
The consensus among analysts is that 'Revenues- Applied Sterilization Technologies' will reach $253.02 million. The estimate indicates a change of +7.6% from the prior-year quarter.
Analysts predict that the 'Revenues- Life Sciences' will reach $132.97 million. The estimate suggests a change of -0.1% year over year.
It is projected by analysts that the 'Revenues- Life Sciences- Service' will reach $36.33 million. The estimate indicates a year-over-year change of -5%.
According to the collective judgment of analysts, 'Revenues- Life Sciences- Consumables' should come in at $67.01 million. The estimate indicates a change of +12.8% from the prior-year quarter.
The consensus estimate for 'Revenues- Life Sciences- Capital equipment' stands at $31.04 million. The estimate suggests a change of -12.4% year over year.
Analysts forecast 'Operating income / (loss)- Healthcare' to reach $220.37 million. The estimate compares to the year-ago value of $204.05 million.
Analysts expect 'Operating income / (loss)- Applied Sterilization Technologies' to come in at $119.53 million. The estimate is in contrast to the year-ago figure of $110.78 million.
The combined assessment of analysts suggests that 'Operating income / (loss)- Life Sciences' will likely reach $54.33 million. The estimate compares to the year-ago value of $50.28 million.
Over the past month, shares of Steris have returned -4.7% versus the Zacks S&P 500 composite's -1% change. Currently, STE carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Steris (STE) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Wall Street analysts expect Steris (STE - Free Report) to post quarterly earnings of $2.11 per share in its upcoming report, which indicates a year-over-year increase of 3.9%. Revenues are expected to be $1.34 billion, down 0.4% from the year-ago quarter.
Over the last 30 days, there has been a downward revision of 1.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Steris metrics that Wall Street analysts commonly model and monitor.
Analysts' assessment points toward 'Revenues- Healthcare' reaching $950.73 million. The estimate indicates a year-over-year change of +9.3%.
Based on the collective assessment of analysts, 'Revenues- Healthcare Products- Service' should arrive at $342.16 million. The estimate points to a change of +10.7% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Healthcare Products- Capital equipment' of $267.10 million. The estimate indicates a year-over-year change of +4.8%.
The average prediction of analysts places 'Revenues- Healthcare Products- Consumables' at $338.19 million. The estimate suggests a change of +10.5% year over year.
The consensus among analysts is that 'Revenues- Applied Sterilization Technologies' will reach $253.02 million. The estimate indicates a change of +7.6% from the prior-year quarter.
Analysts predict that the 'Revenues- Life Sciences' will reach $132.97 million. The estimate suggests a change of -0.1% year over year.
It is projected by analysts that the 'Revenues- Life Sciences- Service' will reach $36.33 million. The estimate indicates a year-over-year change of -5%.
According to the collective judgment of analysts, 'Revenues- Life Sciences- Consumables' should come in at $67.01 million. The estimate indicates a change of +12.8% from the prior-year quarter.
The consensus estimate for 'Revenues- Life Sciences- Capital equipment' stands at $31.04 million. The estimate suggests a change of -12.4% year over year.
Analysts forecast 'Operating income / (loss)- Healthcare' to reach $220.37 million. The estimate compares to the year-ago value of $204.05 million.
Analysts expect 'Operating income / (loss)- Applied Sterilization Technologies' to come in at $119.53 million. The estimate is in contrast to the year-ago figure of $110.78 million.
The combined assessment of analysts suggests that 'Operating income / (loss)- Life Sciences' will likely reach $54.33 million. The estimate compares to the year-ago value of $50.28 million.
View all Key Company Metrics for Steris here>>>
Over the past month, shares of Steris have returned -4.7% versus the Zacks S&P 500 composite's -1% change. Currently, STE carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>